

# Francois Lamoureux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3706533/publications.pdf>

Version: 2024-02-01

75  
papers

2,320  
citations

186209

28  
h-index

214721

47  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3789  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapies of bone metastases in castration-resistant prostate cancer. , 2022, , 967-975.		0
2	Development of prohibitin ligands against osteoporosis. European Journal of Medicinal Chemistry, 2021, 210, 112961.	2.6	6
3	Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers, 2021, 13, 683.	1.7	71
4	Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues. Cells, 2021, 10, 754.	1.8	17
5	BET bromodomains™ functions in bone-related pathologies. Epigenomics, 2020, 12, 127-144.	1.0	13
6	Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing™s Sarcoma Tumor Growth. Cancers, 2020, 12, 3438.	1.7	8
7	Ribosomopathies: New Therapeutic Perspectives. Cells, 2020, 9, 2080.	1.8	21
8	TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. EBioMedicine, 2020, 53, 102704.	2.7	23
9	Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone Sarcomas. Cells, 2020, 9, 810.	1.8	15
10	Abstract 4673: BET bromodomains epigenetic signaling in osteosarcoma: Localization of super-enhancers and identification of new therapeutic targets. , 2020, , .		0
11	Abstract 3595: Riboprotein variant and their role in chondrogenic differentiation and osteosarcoma development. , 2020, , .		0
12	RPL13 Variants Cause Spondyloepimetaphyseal Dysplasia with Severe Short Stature. American Journal of Human Genetics, 2019, 105, 1040-1047.	2.6	17
13	Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 2019, 44, 452-466.	2.7	30
14	Analysis of mRNA, miRNA, and DNA in Bone Cells by RT-qPCR and In Situ Hybridization. Methods in Molecular Biology, 2019, 1914, 169-196.	0.4	2
15	Implication of molecular vascular smooth muscle cell heterogeneity among arterial beds in arterial calcification. PLoS ONE, 2018, 13, e0191976.	1.1	25
16	Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma. Oncotarget, 2018, 9, 35726-35741.	0.8	16
17	Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Bone, 2017, 94, 10-21.	1.4	51
18	Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget, 2016, 7, 24125-24140.	0.8	42

#	ARTICLE	IF	CITATIONS
19	Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2142.	1.8	129
20	$^{125}\text{I}$ -Np63 $\beta$ Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGF $\beta$ <sup>2</sup> -Induced Metastasis. <i>Cancer Research</i> , 2016, 76, 3236-3251.	0.4	48
21	Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression. <i>Clinical Cancer Research</i> , 2016, 22, 2520-2533.	3.2	32
22	miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors. <i>Oncotarget</i> , 2016, 7, 54503-54514.	0.8	37
23	Abstract B46: miRNA-193a-5p repression of p73 induces Cisplatin chemoresistance in bone-related sarcomas. , 2016, , .		0
24	Abstract 1911: $^{125}\text{I}$ -Np63 $\beta$ promotes TGF $\beta$ <sup>2</sup> -induced metastasis by silencing a microRNA network restraining wound healing. , 2016, , .		0
25	Abstract 4472: Targeting the oncogenic transcription factor EWS-Fli1 by BET bromodomain inhibition in Ewing sarcoma. , 2016, , .		0
26	BYL719, a new $\text{I}\beta$ -specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. <i>International Journal of Cancer</i> , 2015, 136, 784-796.	2.3	53
27	Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view. , 2015, , 637-646.		1
28	Abstract 1750: Preclinical efficacy of Hsp90 inhibition by using PF-04942847 in osteosarcoma. , 2015, , .		0
29	Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer. <i>European Urology</i> , 2014, 66, 145-155.	0.9	70
30	Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. <i>Nature Communications</i> , 2014, 5, 3511.	5.8	121
31	Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. <i>BMC Cancer</i> , 2014, 14, 169.	1.1	25
32	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. <i>Oncotarget</i> , 2014, 5, 7805-7819.	0.8	27
33	Abstract LB-142: Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle. , 2014, , .		0
34	Abstract A50: Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle. , 2014, , .		0
35	Osteoprotegerin: Multiple partners for multiple functions. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 401-409.	3.2	115
36	Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2342-2355.	1.9	120

#	ARTICLE	IF	CITATIONS
37	318 SYNERGISTIC TARGETING OF PI3K/AKT-PATHWAY AND ANDROGEN-RECEPTOR AXIS SIGNIFICANTLY DELAYS CASTRATION-RESISTANT PROSTATE CANCER PROGRESSION IN VIVO. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
38	Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL. <i>Journal of Bone Oncology</i> , 2013, 2, 95-104.	1.0	5
39	Molecular Mechanisms of Castrate Resistant Prostate Cancer. , 2013, , 43-64.		1
40	A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>in Vitro</i> and <i>in Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 567-576.	1.9	94
41	Dual inhibition of autophagy and the AKT pathway in prostate cancer. <i>Autophagy</i> , 2013, 9, 1119-1120.	4.3	45
42	Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363. <i>Clinical Cancer Research</i> , 2013, 19, 833-844.	3.2	86
43	Abstract B53: Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors. , 2013, , .		0
44	Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC- $\beta$ Abolishes Ewing Sarcoma Growth. <i>Cancer Research</i> , 2012, 72, 4494-4503.	0.4	59
45	972 A NOVEL ANTIANDROGEN PF-05234848 SUPPRESSES CASTRATION-RESISTANT AND MDV-3100-RESISTANT PROSTATE CANCER GROWTH IN VITRO AND IN VIVO. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
46	Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor axis in castration-resistant prostate tumors. <i>Prostate</i> , 2012, 72, 875-885.	1.2	12
47	613 IMMEDIATE, COMPARED TO DEFERRED, COMBINED ANDROGEN BLOCKADE PROLONGS TIME TO CASTRATE-RESISTANT LNCAP PROSTATE CANCER PROGRESSION IN VIVO. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
48	728 AZD5363, A NOVEL AKT INHIBITOR, DELAYS PROSTATE CANCER PROGRESSION. <i>Journal of Urology</i> , 2011, 185, .	0.2	2
49	1279 CLU INHIBITION USING OGX-011 IS A NEW ADJUVANT THERAPEUTIC STRATEGY FOR HSP90 INHIBITION IN PROSTATE CANCER. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
50	606 CARBIDOPA ENHANCES ANTITUMORAL ACTIVITY OF BICALUTAMIDE ON THE ANDROGEN RECEPTOR-AXIS IN CASTRATION-RESISTANT PROSTATE TUMORS. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
51	Formulated siRNAs targeting <i>Rankl</i> prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2452-2462.	3.1	34
52	Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 5838-5849.	0.4	84
53	Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 347-359.	1.9	57
54	A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis. <i>Clinical Cancer Research</i> , 2011, 17, 2301-2313.	3.2	57

#	ARTICLE	IF	CITATIONS
55	Abstract 4491: AZD5363, a novel Akt inhibitor, delays prostate cancer progression by inhibiting androgen-receptor activity. , 2011, , .		0
56	Abstract 1595: Use of MDV3100 to establish androgen-receptor antagonist resistant LNCaP cells for modelling castrate-resistant progression. , 2011, , .		0
57	Abstract 623: CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer. , 2011, , .		0
58	Animal Models of Malignant Primary Bone Tumors and Novel Therapeutic Approaches. , 2010, , 333-346.		1
59	Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival. <i>Clinical Cancer Research</i> , 2010, 16, 2363-2374.	3.2	57
60	Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients. <i>Cancer Research</i> , 2010, 70, 7610-7619.	0.4	73
61	1298 THE NOVEL HSP90 INHIBITOR, PF-04929113, INHIBITS AR ACTIVITY AND OSTEOCLASTOGENESIS AND DELAYS CASTRATE RESISTANT LNCAP PROSTATE CANCER TUMOR GROWTH. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
62	Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma. <i>Cancer Research</i> , 2009, 69, 526-536.	0.4	47
63	Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. <i>International Journal of Cancer</i> , 2008, 122, 751-760.	2.3	15
64	TNF-Related Apoptosis Inducing Ligand (TRAIL) inhibits primary bone tumor growth and augments survival in a human model ewing sarcoma. <i>Bone</i> , 2008, 42, S94.	1.4	0
65	P45. TNF-related apoptosis-inducing ligand (TRAIL) inhibits primary bone tumor growth and augments survival in a human model Ewing sarcoma. <i>Cancer Treatment Reviews</i> , 2008, 34, 36.	3.4	0
66	P46. Proteoglycans are potential regulators of osteoprotegerin (OPG) antitumoral and anti-bone resorption activities in osteosarcoma. <i>Cancer Treatment Reviews</i> , 2008, 34, 36-37.	3.4	0
67	P47. Therapeutic efficacy of soluble receptor activator of NF-kappaB delivered by non-viral gene transfer in a mouse model of osteolytic osteosarcoma. <i>Cancer Treatment Reviews</i> , 2008, 34, 37.	3.4	0
68	Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats. <i>Cancer Research</i> , 2008, 68, 9433-9440.	0.4	32
69	Therapeutic efficacy of soluble receptor activator of nuclear factor- $\kappa$ B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3389-3398.	1.9	45
70	Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 178-186.	0.8	7
71	Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption. <i>Cancer Research</i> , 2007, 67, 7308-7318.	0.4	160
72	Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 169-181.	1.1	87

#	ARTICLE	IF	CITATIONS
73	Proteoglycans: key partners in bone cell biology. <i>BioEssays</i> , 2007, 29, 758-771.	1.2	81
74	RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. <i>International Journal of Oncology</i> , 2006, 28, 261.	1.4	22
75	RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. <i>International Journal of Oncology</i> , 2006, 28, 261-9.	1.4	22